198 related articles for article (PubMed ID: 23144888)
1. Prime-boost vaccination with SA-4-1BBL costimulatory molecule and survivin eradicates lung carcinoma in CD8+ T and NK cell dependent manner.
Srivastava AK; Sharma RK; Yolcu ES; Ulker V; MacLeod K; Dinc G; Shirwan H
PLoS One; 2012; 7(11):e48463. PubMed ID: 23144888
[TBL] [Abstract][Full Text] [Related]
2. Costimulation as a platform for the development of vaccines: a peptide-based vaccine containing a novel form of 4-1BB ligand eradicates established tumors.
Sharma RK; Elpek KG; Yolcu ES; Schabowsky RH; Zhao H; Bandura-Morgan L; Shirwan H
Cancer Res; 2009 May; 69(10):4319-26. PubMed ID: 19435920
[TBL] [Abstract][Full Text] [Related]
3. SA-4-1BBL as the immunomodulatory component of a HPV-16 E7 protein based vaccine shows robust therapeutic efficacy in a mouse cervical cancer model.
Sharma RK; Srivastava AK; Yolcu ES; MacLeod KJ; Schabowsky RH; Madireddi S; Shirwan H
Vaccine; 2010 Aug; 28(36):5794-802. PubMed ID: 20603135
[TBL] [Abstract][Full Text] [Related]
4. 4-1BB ligand as an effective multifunctional immunomodulator and antigen delivery vehicle for the development of therapeutic cancer vaccines.
Sharma RK; Schabowsky RH; Srivastava AK; Elpek KG; Madireddi S; Zhao H; Zhong Z; Miller RW; Macleod KJ; Yolcu ES; Shirwan H
Cancer Res; 2010 May; 70(10):3945-54. PubMed ID: 20406989
[TBL] [Abstract][Full Text] [Related]
5. A Novel Form of 4-1BBL Prevents Cancer Development via Nonspecific Activation of CD4
Barsoumian HB; Batra L; Shrestha P; Bowen WS; Zhao H; Egilmez NK; Gomez-Gutierrez JG; Yolcu ES; Shirwan H
Cancer Res; 2019 Feb; 79(4):783-794. PubMed ID: 30770367
[TBL] [Abstract][Full Text] [Related]
6. SA-4-1BBL and monophosphoryl lipid A constitute an efficacious combination adjuvant for cancer vaccines.
Srivastava AK; Dinc G; Sharma RK; Yolcu ES; Zhao H; Shirwan H
Cancer Res; 2014 Nov; 74(22):6441-51. PubMed ID: 25252915
[TBL] [Abstract][Full Text] [Related]
7. CD4+ T cells play a critical role in the generation of primary and memory antitumor immune responses elicited by SA-4-1BBL and TAA-based vaccines in mouse tumor models.
Sharma RK; Yolcu ES; Srivastava AK; Shirwan H
PLoS One; 2013; 8(9):e73145. PubMed ID: 24066030
[TBL] [Abstract][Full Text] [Related]
8. CD4 T-cells transduced with CD80 and 4-1BBL mRNA induce long-term CD8 T-cell responses resulting in potent antitumor effects.
Park HM; Sohn HJ; Kim YJ; Cho HI; Kim TG
Vaccine; 2014 Dec; 32(51):6919-6926. PubMed ID: 25444817
[TBL] [Abstract][Full Text] [Related]
9. Fowlpox-based survivin vaccination for malignant mesothelioma therapy.
Bertino P; Panigada M; Soprana E; Bianchi V; Bertilaccio S; Sanvito F; Rose AH; Yang H; Gaudino G; Hoffmann PR; Siccardi A; Carbone M
Int J Cancer; 2013 Aug; 133(3):612-23. PubMed ID: 23335100
[TBL] [Abstract][Full Text] [Related]
10. An adenoviral cancer vaccine co-encoding a tumor associated antigen together with secreted 4-1BBL leads to delayed tumor progression.
Ragonnaud E; Andersson AM; Pedersen AE; Laursen H; Holst PJ
Vaccine; 2016 Apr; 34(18):2147-56. PubMed ID: 27004934
[TBL] [Abstract][Full Text] [Related]
11. SA-4-1BBL as a novel adjuvant for the development of therapeutic cancer vaccines.
Sharma RK; Yolcu ES; Shirwan H
Expert Rev Vaccines; 2014 Mar; 13(3):387-98. PubMed ID: 24521311
[TBL] [Abstract][Full Text] [Related]
12. 4-1BBL coexpression enhances HIV-specific CD8 T cell memory in a poxvirus prime-boost vaccine.
Harrison JM; Bertram EM; Boyle DB; Coupar BE; Ranasinghe C; Ramshaw IA
Vaccine; 2006 Nov; 24(47-48):6867-74. PubMed ID: 17050052
[TBL] [Abstract][Full Text] [Related]
13. CD4 and CD8 T cell responses to the M. tuberculosis Ag85B-TB10.4 promoted by adjuvanted subunit, adenovector or heterologous prime boost vaccination.
Elvang T; Christensen JP; Billeskov R; Thi Kim Thanh Hoang T; Holst P; Thomsen AR; Andersen P; Dietrich J
PLoS One; 2009; 4(4):e5139. PubMed ID: 19357780
[TBL] [Abstract][Full Text] [Related]
14. Improving the Th1 cellular efficacy of the lead Yersinia pestis rF1-V subunit vaccine using SA-4-1BBL as a novel adjuvant.
Dinc G; Pennington JM; Yolcu ES; Lawrenz MB; Shirwan H
Vaccine; 2014 Sep; 32(39):5035-40. PubMed ID: 25045812
[TBL] [Abstract][Full Text] [Related]
15. Highly persistent and effective prime/boost regimens against tuberculosis that use a multivalent modified vaccine virus Ankara-based tuberculosis vaccine with interleukin-15 as a molecular adjuvant.
Kolibab K; Yang A; Derrick SC; Waldmann TA; Perera LP; Morris SL
Clin Vaccine Immunol; 2010 May; 17(5):793-801. PubMed ID: 20357059
[TBL] [Abstract][Full Text] [Related]
16. A switch in costimulation from CD28 to 4-1BB during primary versus secondary CD8 T cell response to influenza in vivo.
Bertram EM; Dawicki W; Sedgmen B; Bramson JL; Lynch DH; Watts TH
J Immunol; 2004 Jan; 172(2):981-8. PubMed ID: 14707071
[TBL] [Abstract][Full Text] [Related]
17. A DNA-based cancer vaccine enhances lymphocyte cross talk by engaging the NKG2D receptor.
Zhou H; Luo Y; Kaplan CD; Krüger JA; Lee SH; Xiang R; Reisfeld RA
Blood; 2006 Apr; 107(8):3251-7. PubMed ID: 16368879
[TBL] [Abstract][Full Text] [Related]
18. 4-1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T cells with similar efficacy.
Cannons JL; Lau P; Ghumman B; DeBenedette MA; Yagita H; Okumura K; Watts TH
J Immunol; 2001 Aug; 167(3):1313-24. PubMed ID: 11466348
[TBL] [Abstract][Full Text] [Related]
19. DNA and adenovirus tumor vaccine expressing truncated survivin generates specific immune responses and anti-tumor effects in a murine melanoma model.
Zhang H; Wang Y; Liu C; Zhang L; Xia Q; Zhang Y; Wu J; Jiang C; Chen Y; Wu Y; Zha X; Yu X; Kong W
Cancer Immunol Immunother; 2012 Oct; 61(10):1857-67. PubMed ID: 22706381
[TBL] [Abstract][Full Text] [Related]
20. 4-1BB ligand enhances tumor-specific immunity of poxvirus vaccines.
Kudo-Saito C; Hodge JW; Kwak H; Kim-Schulze S; Schlom J; Kaufman HL
Vaccine; 2006 Jun; 24(23):4975-86. PubMed ID: 16621183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
